Eupraxia Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Eupraxia Pharmaceuticals's earnings have been declining at an average annual rate of -39.4%, while the Biotechs industry saw earnings growing at 16.6% annually.
Key information
-39.4%
Earnings growth rate
-4.5%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -172.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Eupraxia Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -30 | 9 | 22 |
| 31 Dec 23 | 0 | -28 | 7 | 21 |
| 30 Sep 23 | 0 | -25 | 7 | 15 |
| 30 Jun 23 | 0 | -24 | 5 | 14 |
| 31 Mar 23 | 0 | -20 | 4 | 14 |
| 31 Dec 22 | 0 | -18 | 4 | 14 |
| 30 Sep 22 | 0 | -14 | 5 | 9 |
| 30 Jun 22 | 0 | -14 | 4 | 10 |
| 31 Mar 22 | 0 | -14 | 5 | 9 |
| 31 Dec 21 | 0 | -19 | 6 | 8 |
| 30 Sep 21 | 0 | -15 | 3 | 6 |
| 30 Jun 21 | 0 | -12 | 5 | 3 |
| 31 Mar 21 | 0 | -9 | 4 | 1 |
| 31 Dec 20 | 0 | -3 | 1 | 1 |
| 30 Sep 20 | 0 | -3 | 1 | 0 |
| 31 Dec 19 | 0 | -6 | 2 | 2 |
| 31 Dec 18 | 0 | -10 | 4 | 5 |
Quality Earnings: EPRX is currently unprofitable.
Growing Profit Margin: EPRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EPRX is unprofitable, and losses have increased over the past 5 years at a rate of 39.4% per year.
Accelerating Growth: Unable to compare EPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EPRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: EPRX has a negative Return on Equity (-172.13%), as it is currently unprofitable.